ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions
Humaid O Al-Shamsi, Saeed Rafii, Syed Hammad Hassan Tirmazy, Deborah Mukherji, Ahmad Y Abuhelwa, Faryal Iqbal, Siddig Ibrahim Abdelwahab, Hampig Raphael Kourie, Maen Abdelrahim · 2026
Read ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions by Humaid O Al-Shamsi, Saeed Rafii, Syed Hammad Hassan Tirmazy, Deborah Mukherji, Ahmad Y Abuhelwa, Faryal Iqbal, Siddig Ibrahim Abdelwahab, Hampig Raphael Kourie, Maen Abdelrahim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13589515.txt.
Description
Humaid Al-Shamsi and co-authors review a blood test in a 2026 paper on bowel cancer care. Fragments of tumor DNA in the blood can reveal leftover disease after surgery, long before scans do. The review sorts proof of accuracy from proof of benefit, a distinction the authors stress throughout.
A positive test after surgery consistently marks far higher relapse risk, and repeated tests add more signal. One trial showed test-guided care safely cut chemo use in stage two disease. Two later trials, though, failed to prove that acting on the test improves outcomes. Guidance today urges caution. The authors map weak-shedding tumors, blood-cell noise, and test styles as open problems for the field.
Catalog record
| CREATOR | Humaid O Al-Shamsi, Saeed Rafii, Syed Hammad Hassan Tirmazy, Deborah Mukherji, Ahmad Y Abuhelwa, Faryal Iqbal, Siddig Ibrahim Abdelwahab, Hampig Raphael Kourie, Maen Abdelrahim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |